Biomarker Core

生物标志物核心

• 批准号: 10647878
• 负责人: TONY WYSS-CORAY
• 金额: $ 34.47万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10647878
• 关键词: Algorithmic Analysis; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer’s disease biomarker; Amyloid beta-42; Amyloid beta-Protein; Bioinformatics; Biological Assay; Biological Markers; Biology; Blood; Blood Cells; Cardiovascular Diseases; Cells; Clinical; Clinical Management; Collaborations; Collection; Cytometry; DNA; Data; Data Analyses; Data Set; Databases; Dedications; Dementia; Detection; Development; Diabetes Mellitus; Disease; Equipment and supply inventories; Feces; Fibroblasts; Gene Expression; Genetic; Glial Fibrillary Acidic Protein; Goals; Human; Image; Immune; Individual; Information Dissemination; Light; Liquid substance; Measurement; Measures; Methods; Mission; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Parkinson' s Dementia; Participant; Pathologic Processes; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Populations at Risk; Process; Proteome; Proteomics; Publishing; Quality Control; RNA; Reproducibility; Research; Research Personnel; Sampling; Sensitivity and Specificity; Serum; Signal Transduction; Skin; Source; Standardization; T-Cell Receptor; Technology; Tissues; Training Support; Work; analysis pipeline; bioinformatics tool; biomarker performance; data management; data sharing; experience; genetic variant; gut microbiome; imaging modality; member; microbiome; molecular marker; multiple omics; neurofilament; neuropathology; next generation; novel; novel marker; novel therapeutics; public database; receptor expression; research study; skin microbiome; stool sample; tau Proteins; tau-1; tool; transcriptome; transcriptome sequencing; transcriptomics; web portal; whole genome

1. SUMMARY (Biomarker Core) Biomarkers have enormous value for the detection, management, and treatment of disease, but also for the development of novel therapeutics. The utility of biomarkers is most evident in the management of cardiovascular disease and diabetes, but biomarkers, especially predictive, easily obtainable ones, are still largely absent with respect to neurodegenerative diseases. The best fluid biomarkers currently available for Alzheimer’s disease (AD) include; Aβ, tau, and neurofilament in CSF, a biofluid which is difficult to collect in healthy, at-risk populations or on a repeated basis. Other biomarkers for AD include imaging modalities which are often very expensive or have low sensitivity and specificity at the individual level. The members of this core have considerable experience in unbiased multi-omic screens and data analysis and, over the years, have published numerous studies towards developing new biomarkers for neurodegenerative and other diseases. Enabled by the current ADRC, the core leaders and collaborators have used biospecimens from Stanford ADRC participants and generated extensive preliminary data with unbiased deep immune phenotyping, proteomics, and transcriptomics of human CSF resident cells, and discovered novel Parkinson's disease (PD) biomarkers. Based on this expertise, the mission of this Biomarker Core is to facilitate the discovery of novel biomarkers for AD and PD, as well as new biology underlying the pathological processes that lead to dementia in line with the core mission of the NAPA. This will be achieved by pursuing the collection of genetic and molecular measurements from a broad source of tissues from ADRC participants; the processing and dissemination of this information in useable formats through web portals and other means (i.e., “Deep Phenotyping Database”); the analysis and bioinformatics integration of the collected information with clinical and imaging data, as well as information from public databases; and the development and dissemination of new data analysis algorithms and pipelines.

1. 摘要（生物标志物核心） 生物标志物对于疾病的检测、管理和治疗具有巨大的价值，而且对于 生物标志物的实用性在治疗小说的发展中最为明显。 心血管疾病和糖尿病，但生物标志物，尤其是预测性的、容易获得的生物标志物，仍然是 目前可用于神经退行性疾病的最佳液体生物标志物基本上不存在。 阿尔茨海默病 (AD) 包括：脑脊液中的 Aβ、tau 蛋白和神经丝，这是一种很难在体内收集的生物液。 健康、高危人群或重复的 AD 生物标志物包括成像方式。 通常非常昂贵或在个体水平上灵敏度和特异性较低。 在公正的多组学筛选和数据分析方面拥有丰富的经验，多年来， 为了开发神经退行性疾病和其他疾病的新生物标志物，发表了许多研究。 在当前 ADRC 的支持下，核心领导者和合作者使用了斯坦福大学的生物样本 ADRC 参与者并通过公正的深度免疫表型分析生成了广泛的初步数据， 人类脑脊液常驻细胞的蛋白质组学和转录组学，并发现了新型帕金森病 (PD) 基于这些专业知识，该生物标记核心的使命是促进新发现。 AD 和 PD 的生物标志物，以及导致痴呆的病理过程的新生物学 这符合 NAPA 的核心使命，这将通过收集基因和信息来实现。 来自 ADRC 参与者的广泛组织来源的分子测量； 通过门户网站和其他方式（即“深度 表型数据库”）；将收集到的信息与临床进行分析和生物信息学整合 和成像数据以及公共数据库的信息；以及 新的数据分析算法和管道。